Pfizer Could Prove Underrated GLP-1 Stock Opportunity
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...
Pharma
This Pharma tag page compiles 4 recent articles on Moderna, Lilly, ANIP, and pharma dividends to help you spot opportunities and manage risk in your portfolio.
27 articlesPfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Medicare Price Cuts on 10 Drugs, Biggest 79% Drop This Year
Medicare's first round of drug-price negotiations slashes list prices on 10 widely used drugs by up to 79% starting J...
Medicare’s $2,100 Drug Quietly Reshapes Prescription Costs for Investors
Medicare's out-of-pocket cap for covered prescriptions rises to $2,100 in 2026, ending the donut-hole-era for many pa...
Prediction: Lilly Will Trade at Record High in 12 Months
Eli Lilly stock is surging on fresh obesity-drug data, fueling bets that the name could push toward a record high wit...
Will Johnson & Johnson Stock Reach $300 This Year?
With Johnson & Johnson stock hovering near mid-230s, investors are weighing if a $300 target is in reach this year as...
Indiana's 150-Year-Old Firm Aims Global Dominance in Five Years
A century-and-a-half-old Indiana company is drawing fresh investor attention with a plan to become the world's larges...
Lilly Stock Jumps After Phase 3 Weight-Drug Readout
Lilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
Investors Seek GLP-1 Alternatives After Nausea Hurdles
A new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
Health Just Announced Fantastic News for Lilly Investors
A major payer shift could unlock stronger demand for Eli Lilly’s obesity and GLP-1 products. This in-depth analysis e...
Merck: Navigating Patent Cliff and Growth Prospects
Merck faces the challenge of expiring patents while pushing a robust pipeline and disciplined capital moves. This gui...
Loves Autodidacts, Desperately Needs AI-Driven Leaders
A high-profile CEO champions self-taught, AI-fluent leadership while leaning on a deep bench of scientists. The piece...